APLM
ACHAT TOTAL: 130000 titres (~1950000 USD)
- Insiders
- Chen Hung-Wen, LIN PETER KUAN-HOW
- Total bought
- $1,950,000
- Total sold
- —
- Last activity
- 2026-08-14
- Last synced
-
2026-08-21 23:36:53
Insider holdings as a share of total assets aren't available for this company.
Price (1 year)
Live chart from TradingView - pulls its own market data, independent of this site's database. Symbol resolution is best-effort (defaults to NASDAQ) since we don't store the exchange prefix.
Market snapshot
Signal
Bearish signal Scored 2026-09-06
APLM presents a meaningful insider cluster buy signal (~$1.95M, 130k shares) following a $10M private placement, suggesting insiders may see a near-term clinical runway extension — however, this catalytic confidence…
The first sentence of the analysis written for APLM on 2026-09-06 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 97.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Ebit Margin | -111.4% | -20771.2% | -6522.4% | -13642.4% | -2513500.0% | |
| Ebitda Margin | -108.4% | -20734.8% | -6509.9% | -13586.1% | -2505850.0% | |
| Operating Profit Margin | -111.4% | -21280.8% | -6578.9% | -13957.0% | -2542850.0% | |
| Pretax Profit Margin | -128.7% | -27070.2% | -21022.0% | -74554.2% | -4739800.0% | |
| Continuous Operations Profit Margin | -128.7% | -27201.0% | -21023.3% | -74554.5% | -4739850.0% | |
| Net Profit Margin | -128.7% | -27201.0% | -21023.3% | -74554.5% | -4739850.0% | |
| Bottom Line Profit Margin | -128.7% | -27201.0% | -21023.3% | -74554.5% | -4739850.0% | |
| Current Ratio | 0.957 | 1.388 | 2.945 | 4.515 | 7.330 | |
| Quick Ratio | 0.957 | 1.388 | 2.945 | 4.515 | 7.164 | |
| Solvency Ratio | -1.079 | -6.532 | -12.188 | -0.459 | -0.281 | |
| Cash Ratio | 0.518 | 1.320 | 2.365 | 2.644 | 3.448 | |
| Price To Earnings Ratio | -2.470 | -0.185 | -0.416 | -16.818 | -42.345 | |
| Price To Earnings Growth Ratio | 0.029 | 0.002 | -0.002 | -0.103 | -3.187 | |
| Forward Price To Earnings Growth Ratio | 0.029 | 0.002 | -0.002 | -0.103 | -3.187 | |
| Price To Earnings Diluted Ratio | -2.470 | -0.185 | -0.416 | -16.818 | -42.345 | |
| Price To Earnings Diluted Growth Ratio | 0.029 | 0.002 | -0.002 | -0.103 | -3.187 | |
| Price To Book Ratio | -8.476 | 1.857 | 1.741 | -2.007 | -4.049 | |
| Price To Sales Ratio | 3.179 | 45.622 | 87.446 | 2,783.915 | 430,941.147 | |
| Price To Free Cash Flow Ratio | -2.606 | -0.314 | -1.661 | -20.819 | -16.946 | |
| Price To Operating Cash Flow Ratio | -2.606 | -0.314 | -1.662 | -20.998 | -19.899 | |
| Debt To Assets Ratio | 0.096 | 0.074 | 0.084 | 0.013 | 2.636 | |
| Debt To Equity Ratio | -0.202 | 0.199 | 0.113 | -0.002 | -1.529 | |
| Debt To Capital Ratio | -0.253 | 0.166 | 0.102 | -0.002 | 2.891 | |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 2.947 | |
| Financial Leverage Ratio | -2.106 | 2.693 | 1.343 | -0.171 | -0.580 | |
| Working Capital Turnover Ratio | 6.556 | 0.014 | 0.024 | 0.005 | 0.000 | |
| Operating Cash Flow Ratio | -1.639 | -3.885 | -3.187 | -3.466 | -3.195 | |
| Operating Cash Flow Sales Ratio | -1.220 | -145.167 | -52.630 | -132.582 | -21,656.000 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.000 | 1.001 | 1.000 | 1.009 | 1.174 | |
| Debt Service Coverage Ratio | -141.862 | -230.804 | -12.188 | -471.871 | -22.394 | |
| Interest Coverage Ratio | -145.738 | -235.397 | -360.087 | -484.742 | -612.735 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | -10.200 | 0.000 | -20.098 | |
| Operating Cash Flow Coverage Ratio | -16.126 | -29.755 | -9.270 | -43.213 | -0.133 | |
| Capital Expenditure Coverage Ratio | 0.000 | -1,197.625 | -7,201.500 | -116.687 | -5.737 | |
| Dividend Paid And Capex Coverage Ratio | 0.000 | -1,197.625 | -7,201.500 | -116.687 | -5.737 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -2.646 | -0.006 | -0.831 | -19.769 | -22.758 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 97.0% | ▼-3.0% | ▼-2.4% |
| Ebit Margin | -111.5% | ▲20659.8% | ▲510798.0% |
| Ebitda Margin | -108.5% | ▲20626.4% | ▲509249.4% |
| Operating Profit Margin | -111.5% | ▲21169.4% | ▲516844.2% |
| Pretax Profit Margin | -128.7% | ▲26941.5% | ▲972386.4% |
| Continuous Operations Profit Margin | -128.7% | ▲27072.3% | ▲972422.8% |
| Net Profit Margin | -128.7% | ▲27072.3% | ▲972422.8% |
| Bottom Line Profit Margin | -128.7% | ▲27072.3% | ▲972422.8% |
| Current Ratio | 0.957 | ▼-0.431 | ▼-2.470 |
| Quick Ratio | 0.957 | ▼-0.431 | ▼-2.437 |
| Solvency Ratio | -1.079 | ▲5.453 | ▲3.029 |
| Cash Ratio | 0.518 | ▼-0.802 | ▼-1.541 |
| Price To Earnings Ratio | -2.470 | ▼-2.286 | ▲9.977 |
| Price To Earnings Growth Ratio | 0.029 | ▲0.026 | ▲0.681 |
| Forward Price To Earnings Growth Ratio | 0.029 | ▲0.026 | ▲0.681 |
| Price To Earnings Diluted Ratio | -2.470 | ▼-2.286 | ▲9.977 |
| Price To Earnings Diluted Growth Ratio | 0.029 | ▲0.026 | ▲0.681 |
| Price To Book Ratio | -8.476 | ▼-10.333 | ▼-6.289 |
| Price To Sales Ratio | 3.179 | ▼-42.443 | ▼-86769.083 |
| Price To Free Cash Flow Ratio | -2.606 | ▼-2.292 | ▲5.863 |
| Price To Operating Cash Flow Ratio | -2.606 | ▼-2.292 | ▲6.490 |
| Debt To Assets Ratio | 0.096 | ▲0.022 | ▼-0.485 |
| Debt To Equity Ratio | -0.202 | ▼-0.400 | ▲0.083 |
| Debt To Capital Ratio | -0.253 | ▼-0.418 | ▼-0.833 |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | ▼-0.589 |
| Financial Leverage Ratio | -2.106 | ▼-4.799 | ▼-2.342 |
| Working Capital Turnover Ratio | 6.556 | ▲6.543 | ▲5.237 |
| Operating Cash Flow Ratio | -1.639 | ▲2.246 | ▲1.435 |
| Operating Cash Flow Sales Ratio | -1.220 | ▲143.947 | ▲4396.300 |
| Free Cash Flow Operating Cash Flow Ratio | 1.000 | ▼-0.001 | ▼-0.037 |
| Debt Service Coverage Ratio | -141.862 | ▲88.943 | ▲33.962 |
| Interest Coverage Ratio | -145.738 | ▲89.658 | ▲222.001 |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | ▲6.060 |
| Operating Cash Flow Coverage Ratio | -16.126 | ▲13.629 | ▲3.573 |
| Capital Expenditure Coverage Ratio | 0.000 | ▲1197.625 | ▲1704.310 |
| Dividend Paid And Capex Coverage Ratio | 0.000 | ▲1197.625 | ▲1704.310 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -2.646 | ▼-2.640 | ▲6.556 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $27.0M | $9.0M | $71.8M | $899.2M | $861.9M | |
| Enterprise value | $24.4M | $233K | $44.4M | $867.5M | $1.14B | |
| EV / Sales | 2.87x | 1.18x | 54.08x | 2685.82x | 570274.15x | |
| EV / Op. cash flow | -2.35x | -0.01x | -1.03x | -20.26x | -26.33x | |
| EV / Free cash flow | -2.35x | -0.01x | -1.03x | -20.09x | -22.42x | |
| EV / EBITDA | -2.65x | -0.01x | -0.83x | -19.77x | -22.76x | |
| Net debt / EBITDA | 0.29x | 0.21x | 0.51x | 0.72x | -5.56x | |
| Current ratio | 0.96x | 1.39x | 2.94x | 4.51x | 7.33x | |
| Income quality | 0.95x | 0.54x | 0.25x | 0.18x | 0.46x | |
| Graham net-net | -$3 | $2 | $32 | -$541 | -$277 | |
| Tax burden | 100.0% | 100.5% | 100.0% | 100.0% | 100.0% | |
| Interest burden | 115.4% | 130.3% | 322.3% | 546.5% | 188.6% | |
| Working capital | -$275K | $2.9M | $26.4M | $43.4M | $85.8M | |
| Invested capital | $305K | $5.6M | $41.7M | $59.7M | $101.9M | |
| Return on assets | -162.9% | -411.2% | -311.6% | -314.9% | -76.8% | |
| Operating ROA | -95.6% | -123.1% | -81.9% | -45.1% | -34.7% | |
| Return on tangible assets | -162.9% | -474.1% | -424.8% | -390.3% | -87.3% | |
| Return on equity | 343.1% | -1107.3% | -418.6% | 53.7% | 44.5% | |
| Return on invested capital | -1586.8% | -710.3% | -116.8% | -69.6% | -45.2% | |
| Return on capital employed | -2441.5% | -739.4% | -129.1% | -70.3% | -46.3% | |
| Earnings yield | -40.5% | -596.2% | -240.4% | -26.8% | -11.0% | |
| Free cash flow yield | -38.4% | -318.5% | -60.2% | -4.8% | -5.9% | |
| Capex / Op. cash flow | 0.0% | -0.1% | -0.0% | -0.9% | -17.4% | |
| Capex / Depreciation | 0.0% | 6.6% | 0.9% | 47.4% | 1108.7% | |
| Capex / Sales | 0.0% | 12.1% | 0.7% | 113.6% | 377500.0% | |
| SG&A / Sales | 146.4% | 8973.7% | 2514.1% | 3079.6% | 764550.0% | |
| R&D / Sales | 65.1% | 12407.1% | 4164.8% | 10977.4% | 1778400.0% | |
| Stock comp / Sales | -11.5% | 5518.2% | 1545.1% | 1109.0% | 406100.0% | |
| Intangibles / Total assets | 0.0% | 13.3% | 26.6% | 19.3% | 12.0% | |
| Days sales outstanding | 107d | 234d | 207d | 618d | 92345d | |
| Days payables outstanding | 0d | 0d | 0d | 0d | 0d | |
| Operating cycle | 107d | 234d | 207d | 618d | 92345d | |
| Cash conversion cycle | 107d | 234d | 207d | 618d | 92345d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▲+199.1%EV / Sales ▲+143.7%EV / EBITDA ▼-46494.2%EV / Op. cash flow ▼-2.344Earnings yield ▲+5.557
Profitability
Return on equity ▲+14.504Return on assets ▲+2.483Return on invested capital ▼-8.765Return on capital employed ▼-17.021Operating ROA ▲+0.274Income quality ▲+0.412Tax burden ▼-0.005
Efficiency
Days sales outstanding ▼-127.193Days payables outstanding n/aOperating cycle ▼-127.193Cash conversion cycle ▼-127.193Capex / Sales ▼-0.121R&D / Sales ▼-123.420
Balance-sheet strength
Current ratio ▼-0.431Net debt / EBITDA ▲+0.071Working capital ▼-3143000.000Invested capital ▼-5319000.000Intangibles / Total assets ▼-0.133
Change over 5 years
Valuation
Market cap ▼-96.9%EV / Sales ▼-100.0%EV / EBITDA ▲+88.4%EV / Op. cash flow ▲+23.981Earnings yield ▼-0.295
Profitability
Return on equity ▲+2.986Return on assets ▼-0.861Return on invested capital ▼-15.416Return on capital employed ▼-23.952Operating ROA ▼-0.610Income quality ▲+0.491Tax burden +0.000
Efficiency
Days sales outstanding ▼-92238.076Days payables outstanding n/aOperating cycle ▼-92238.076Cash conversion cycle ▼-92238.076Capex / Sales ▼-3775.000R&D / Sales ▼-17783.349
Balance-sheet strength
Current ratio ▼-6.374Net debt / EBITDA ▲+5.846Working capital ▼-86087000.000Invested capital ▼-101621000.000Intangibles / Total assets ▼-0.120
Employee count
Peer market caps
Congressional trades
No congressional trade data synced.
Recent news
- 2026-08-11 Apollomics Announces $10 Million Private Placement Transaction FOSTER CITY, Calif., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM ) (“Apollomics” or the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today announced that it has entered into definitive subscription agreements (the “Subscription Agreements”) for a private placement transaction (the “Private Placement”) with certain accredited investors (the “Investors”), for an aggregate gross consideration of approximately $10.0 million. The Private Placement is expected to close on or about August 14, 2026, subject to the satisfaction of customary closing conditions.
- 2026-07-13 Apollomics Regains Full Compliance with Nasdaq Listing Requirements FOSTER CITY, Calif., July 13, 2026 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM ) (“Apollomics” or the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today announced that on July 8, 2026, it received written notice from the Nasdaq Listing Qualifications Staff (Staff) stating that the Company regained compliance with the Market Value of Listed Securities (MVLS) requirement, as set forth in Nasdaq Listing Rule 5550(b)(2) (Rule) for continued listing on the Nasdaq Capital Market, and the matter is now closed.
- 2026-06-24 Apollomics Receives Nasdaq Deficiency Notice Regarding Minimum Market Value Requirement and Updates Rights for Vebreltinib (APL-101) in Asia FOSTER CITY, Calif., June 24, 2026 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM ) (“Apollomics” or the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today announced that it has received a notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) dated June 18, 2026 stating that the Company is not in compliance with the requirement to maintain a minimum Market Value of Listed Securities (“MVLS”) of $35 million as set forth under Nasdaq Listing Rule for continued listing on The Nasdaq Capital Market.